Orphan CNS diseases
Leveraging solutions for patients
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system (CNS) with high unmet medical need.
- NewsSee allRare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy – special film launchedUpdate on Regulatory Review of leriglitazone in the EUMinoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYXMinoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral AdrenoleukodystrophyMinoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked AdrenoleukodystrophyLeriglitazone’s clinical proof of concept data in Friedreich’s Ataxia published in Neurology GeneticsMinoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in EuropeMinoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy